Rawan Tarawneh

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. pmc Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Ann Neurol 70:274-85. 2011
  2. ncbi request reprint Distinguishing Lewy body dementias from Alzheimer's disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Expert Rev Neurother 7:1499-516. 2007
  3. pmc Biomarkers in translational research of Alzheimer's disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Neuropharmacology 59:310-22. 2010
  4. pmc Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri3Charles F and Joanne Knight Alzheimer Disease Research Center, Wash
    JAMA Neurol 73:561-71. 2016
  5. pmc Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine in St Louis, St Louis, Missouri3The Charles F and Joanne Knight Alzheimer s
    JAMA Neurol 72:656-65. 2015
  6. pmc The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, St Louis, Missouri, USA Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, St Louis, Missouri, USA The Knight Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, St Louis, Missouri, USA
    Cold Spring Harb Perspect Med 2:a006148. 2012
  7. pmc Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    CNS Neurol Disord Drug Targets 8:144-59. 2009
  8. pmc Potential future neuroprotective therapies for neurodegenerative disorders and stroke
    Rawan Tarawneh
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Avenue, Suite 130, St Louis, MO 63108, USA
    Clin Geriatr Med 26:125-47. 2010

Detail Information

Publications8

  1. pmc Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Ann Neurol 70:274-85. 2011
    ..Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. Here we investigate CSF VILIP-1 and VILIP-1/amyloid-β42 (Aβ42) ratio as diagnostic and prognostic markers in early AD...
  2. ncbi request reprint Distinguishing Lewy body dementias from Alzheimer's disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Expert Rev Neurother 7:1499-516. 2007
    ..Improved understanding of disease mechanisms may open new therapeutic avenues for LBD in the future...
  3. pmc Biomarkers in translational research of Alzheimer's disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Neuropharmacology 59:310-22. 2010
    ..Such individuals are the most likely to benefit from future disease modifying/prevention therapies as they become available, and therefore represent the population in which the field can make the biggest therapeutic impact...
  4. pmc Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri3Charles F and Joanne Knight Alzheimer Disease Research Center, Wash
    JAMA Neurol 73:561-71. 2016
    ..Synaptic loss is an early pathologic substrate of Alzheimer disease (AD). Neurogranin is a postsynaptic neuronal protein that has demonstrated utility as a cerebrospinal fluid (CSF) marker of synaptic loss in AD...
  5. pmc Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine in St Louis, St Louis, Missouri3The Charles F and Joanne Knight Alzheimer s
    JAMA Neurol 72:656-65. 2015
    ..Visinin-like protein 1 (VILIP-1) has demonstrated potential usefulness as a marker of neuronal injury in AD...
  6. pmc The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, St Louis, Missouri, USA Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, St Louis, Missouri, USA The Knight Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, St Louis, Missouri, USA
    Cold Spring Harb Perspect Med 2:a006148. 2012
    ....
  7. pmc Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    CNS Neurol Disord Drug Targets 8:144-59. 2009
    ..Current work with AD biomarkers suggests that such individuals can now be identified and it seems likely that targeting this population with immunization strategies targeting Abeta would offer the best chance of success...
  8. pmc Potential future neuroprotective therapies for neurodegenerative disorders and stroke
    Rawan Tarawneh
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Avenue, Suite 130, St Louis, MO 63108, USA
    Clin Geriatr Med 26:125-47. 2010
    ..Although most of these therapies are experimental, and require further investigation, a few seem to offer promise...